September 18th, 2014
Do Hemodynamic Endpoints Have Value in Patients Treated for Pulmonary Arterial Hypertension?
Corey E Ventetuolo, MD, MS
Corey E. Ventetuolo discusses her research group’s study of hemodynamic endpoints in clinical trials of patients with pulmonary arterial hypertension.
NEJM Journal Watch — Recent Cardiology Articles- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise
- Aprocitentan, a Newly Approved Drug for Resistant Hypertension